Bozic Carmen, EVP and CMO, has demonstrated a consistent pattern of selling Vertex Pharmaceuticals (VRTX) shares over the past two years, with no recorded purchases in the same period. According to SEC Form 4 filings, Carmen executed 27 transactions totaling $21.9 million in sales, all concentrated in VRTX. The most recent activity includes six sales between February and March 2026, with individual transactions ranging from $704,864 to $1.85 million. Notably, the sales on March 13 and March 27, 2026, amounted to $1.12 million and $1.05 million, respectively, continuing a trend of high-value disposals.
The transactions reveal a structured approach, with sales often clustered in February and March—coinciding with the company’s annual equity award cycles—as well as mid-year disposals in May and June. For example, in February 2026 alone, Carmen sold over $4.6 million worth of shares across multiple filings. While some transactions were marked as stock option exercises (code "F"), others were outright sales (code "S"). The absence of any buys suggests a deliberate reduction in exposure to VRTX, though the reasons remain undisclosed in the filings. The consistency in timing and magnitude points to a prearranged trading plan rather than reactive market moves.
AI-assisted summary